{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:26Z","timestamp":1793766446212,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["21CHAL02"],"award-info":[{"award-number":["21CHAL02"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["18VALO09"],"award-info":[{"award-number":["18VALO09"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102640","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:47:24Z","timestamp":1785944844000},"page":"102640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Poly(ADP-Ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans With Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-0551","authenticated-orcid":false,"given":"Rhonda L.","family":"Bitting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Giagtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McNair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyotae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":false,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda N.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clgc.2026.102640_bib0001","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102640_bib0002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102640_bib0003","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.clgc.2026.102640_bib0004","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102640_bib0005","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10398","key":"10.1016\/j.clgc.2026.102640_bib0006","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.clgc.2026.102640_bib0007","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102640_bib0008","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102640_bib0009","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102640_bib0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2026.102640_bib0011","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102640_bib0012","unstructured":"PRECISION Registry. PARPi response evaluation for clinical impact and scientific innovation in oncology: the PRECISION registry. https:\/\/www.precision-registry.com\/. Accessed February 12, 2024."},{"issue":"10","key":"10.1016\/j.clgc.2026.102640_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37272","article-title":"Survival outcomes by race and ethnicity in veterans with nonmetastatic castration-resistant prostate cancer","volume":"6","author":"Rasmussen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clgc.2026.102640_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44027","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs Health Care System","volume":"5","author":"Yamoah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102640_bib0015","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/CCI.21.00030","article-title":"Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing","volume":"5","author":"Alba","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clgc.2026.102640_bib0016","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer","volume":"7","author":"Candelieri-Surette","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"5","key":"10.1016\/j.clgc.2026.102640_bib0017","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1177\/0962280213519716","article-title":"The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study","volume":"25","author":"Austin","year":"2016","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"10.1016\/j.clgc.2026.102640_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/CU9.0000000000000244","article-title":"How Agent Orange impacts prostate cancer risk, pathology, and treatment outcomes","volume":"18","author":"Paracha","year":"2024","journal-title":"Curr Urol"},{"key":"10.1016\/j.clgc.2026.102640_bib0019","unstructured":"U.S Food and Drug Administration https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer. Accessed May 2, 2024."},{"issue":"1","key":"10.1016\/j.clgc.2026.102640_bib0020","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.clgc.2026.102640_bib0021","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/cncr.32666","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system","volume":"126","author":"Riviere","year":"2020","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.clgc.2026.102640_bib0022","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102640_bib0023","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41391-024-00866-4","article-title":"Rare histological prostate cancer subtypes: cancer-specific and other-cause mortality","volume":"28","author":"Siech","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102640_bib0024","article-title":"Toward informed selection and interpretation of clinical genomic tests in prostate cancer","volume":"8","author":"Vandekerkhove","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102640_bib0025","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-20-2371","article-title":"Characterizing CDK12-mutated prostate cancers","volume":"27","author":"Rescigno","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102640_bib0026","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-Mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102640_bib0027","doi-asserted-by":"crossref","first-page":"e1129","DOI":"10.1093\/oncolo\/oyad264","article-title":"In reply to \u201cpathogenic\/likely pathogenic somatic CDK12 mutations in black men with prostate cancer","volume":"28","author":"Valle","year":"2023","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.clgc.2026.102640_bib0028","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1016\/S2589-7500(23)00053-5","article-title":"Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis","volume":"5","author":"Sivakumar","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"5","key":"10.1016\/j.clgc.2026.102640_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.9119","article-title":"Somatic tumor next-generation sequencing in US veterans with metastatic prostate cancer","volume":"8","author":"Valle","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.clgc.2026.102640_bib0030","doi-asserted-by":"crossref","first-page":"e1127","DOI":"10.1093\/oncolo\/oyad240","article-title":"Pathogenic\/likely Pathogenic somatic CDK12 mutations in black men with prostate cancer","volume":"28","author":"Sartor","year":"2023","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clgc.2026.102640_bib0031","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/pros.24331","article-title":"Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer","volume":"82","author":"Antonarakis","year":"2022","journal-title":"Prostate"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:15:46Z","timestamp":1793765746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001400"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102640","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Poly(ADP-Ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans With Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102640"}}